We’ve been selected for the Innovate UK Global Incubator Programme in partnership with MaRS Discovery District – joining just 8 UK companies chosen to accelerate AI healthcare innovation in the Canadian market.

The six-month programme (September 2025 – March 2026) connects us directly with North America’s largest urban innovation hub, giving VIOSync access to hospitals, investors, regulatory expertise, and talent networks across Canada’s AI healthcare ecosystem.

Key Programme Highlights

Only 8 UK companies selected for this competitive programme focused on AI/ML applications in healthcare decision-making, diagnostics, and treatment

• Partnership with MaRS Discovery District – supports 1,400 companies across Canada; in 2020 alone, MaRS-supported ventures raised $2.4 billion and generated $1.5 billion in revenue

• Two in-market visits to Toronto (October 2025, March 2026) plus weekly virtual sessions with mentors, sector experts, and Canadian healthcare ecosystem stakeholders

• Fully funded support – Innovate UK covers flights, accommodation, in-market travel, and programme fees

• Dedicated Innovation & Growth Specialist from Innovate UK to maximize programme impact and support continued global scaling beyond March 2026

Why Canada for Clinical AI

Canada ranks among the top five countries globally for commercial AI ventures and holds the highest AI patent rate per million people among G7 nations and China. Toronto hosts the world’s largest concentration of AI startups, 273 companies, making it a natural expansion market for VIOSync.

The Canadian healthcare system shares structural similarities with the NHS, publicly funded, integrated care networks, emphasis on evidence-based medicine, which creates a natural pathway for technologies validated in UK clinical environments. Canada’s supportive regulatory framework for AI innovation, combined with major hospital networks actively deploying clinical AI systems, makes it strategically important for companies building hospital-grade AI platforms.

What the Programme Delivers

Phase 1: Preparation (UK-based)

Two-day workshop with the entire cohort to develop strategic action plans, receive briefings on Canada’s innovation landscape and healthcare sector, and prepare for market engagement.

Phase 2: Incubation (4-6 Months)

First in-market visit (October 2025) to assess tech-market fit, validate preliminary customer interest, and connect with hospitals, government stakeholders, and corporates.

Weekly virtual sessions with MaRS advisors, sector experts, and mentors covering regulatory navigation, partnership development, clinical validation pathways, and market entry strategy.

Second in-market visit (March 2026) including a demo day to showcase achievements, raise profile across Canada’s healthtech ecosystem, and solidify connections with potential partners, customers, and investors.

Phase 3: Exploitation

Continued support from Innovate UK Growth Specialists to leverage programme connections, insights, and relationships for long-term market expansion and global scaling.

What This Means for VIOSync

VIOSync is designed to detect sepsis risk up to 48 hours in advance through real-time multimodal data fusion, Explainable AI outputs, and workflow-integrated clinical guidance. Deployment readiness depends on more than technical performance, it requires understanding hospital data infrastructure, regulatory requirements, procurement pathways, and clinician adoption patterns.

The MaRS programme gives us direct access to:

• Hospital networks deploying clinical AI – connecting with CTOs, clinical informatics teams, and procurement decision-makers actively evaluating sepsis prediction systems

• Regulatory navigation expertise – understanding Health Canada’s AI/ML medical device pathways and how they compare to CE MDR and FDA requirements

• Investor and corporate partnership networks – introductions to VCs and healthcare corporates actively investing in clinical AI ventures

• AI/ML technical expertise – access to subject matter experts for deep-dive support on deployment challenges, model optimization, and data integration

• Talent recruitment support – guidance on building teams with skills from Canada’s deep AI talent pool

This isn’t an exploratory programme; it’s designed for companies with traction in the UK that are ready to scale internationally. The programme targets companies solving real unmet clinical needs with novel AI technology, which aligns directly with VIOSync’s focus on earlier sepsis detection through Explainable AI and Digital Patient Twins.

Why This Matters Now

Clinical AI adoption is no longer a research question, it’s an implementation challenge. Hospitals globally are moving beyond pilot studies and asking harder questions: Does this integrate with our existing systems? Can clinicians validate the outputs? What happens during edge cases? How do we manage liability?

The companies that succeed in clinical AI won’t be the ones with the highest AUC scores in controlled studies. They’ll be the ones that understand deployment realities, regulatory complexity, procurement timelines, data interoperability constraints, and clinical workflow integration.

Participating in the Innovate UK Global Incubator Programme gives us structured exposure to these realities in a market that shares regulatory alignment with the UK while offering significant scale opportunities in North America.

Looking Ahead: October 2025 to March 2026

The programme kicks off with preparation workshops in September 2025, followed by our first market visit to Toronto in October. We’ll be connecting with hospital systems, meeting with regulatory advisors, and establishing relationships that support long-term market entry.

By March 2026, we’ll have deep insight into Canada’s clinical AI landscape, validated tech-market fit with Canadian healthcare stakeholders, and established partnerships that enable scalable deployment beyond the UK.

For anyone interested in following our progress through the programme or exploring collaboration opportunities in Canada, stay tuned for updates as we navigate this next phase of VIOSync global expansion.

About Aisthesis Medical

Aisthesis Medical is a deep-tech medtech startup developing cutting-edge AI-driven solutions to revolutionize acute care. Founded in 2022, our mission is to save lives by predicting and preventing sepsis before it becomes fatal. Aisthesis Medical is revolutionizing acute care with VIOSync, the first holistic AI-driven digital patient twin platform that goes beyond early sepsis prediction to guide clinical intervention and optimize patient outcomes. VIOSync, predicts sepsis up to 48 hours earlier, integrates directly into hospital workflows, and optimizes treatment pathways to reduce unnecessary antibiotic use.

Ready to Learn More?

If you’re a hospital, NHS trust, or healthcare investor interested in learning more about VIOSync or our security and compliance posture, we’d love to connect.

📩 Get in touch: https://aisthesismed.com/contact/

🌐 Learn more about VIOSync: https://aisthesismed.com/product/